Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Wuolikainen, Anna ^a   Moritz, Thomas ^b   Marklund, Stefan L ^a   Antti, Henrik ^a   Andersen, Peter Munch ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMIC ACID; GLUTAMINE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLOME; METABOLOMICS; STATISTICAL MODEL; TIME OF FLIGHT MASS SPECTROMETRY; CASE CONTROL STUDY; CEREBROSPINAL FLUID; ENZYMOLOGY; GENETICS; GENOTYPE; MASS FRAGMENTOGRAPHY; METABOLISM; METHODOLOGY; MUTATION;

AMYOTROPHIC LATERAL SCLEROSIS; CASE-CONTROL STUDIES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENOTYPE; HUMANS; MALE; METABOLOME; METABOLOMICS; MUTATION; SUPEROXIDE DISMUTASE;

EID: 79953717156     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017947     Document Type: Article

References (34)

1. Haverkamp LJ, Appel V, Appel SH, (1995) Natural-History of Amyotrophic-Lateral-Sclerosis in a Database Population- Validation of a Scoring System and a Model for Survival Prediction. Brain 118: 707-719.
2. Li TM, Alberman E, Swash M, (1988) Comparison of Sporadic and Familial Disease Amongst 580 Cases of Motor Neuron Disease. J Neurol Neurosurg Psychiatry 51: 778-784.
3. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, et al. (2005) EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol 12: 921-938.
4. Aggarwal A, Nicholson G, (2002) Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. JNeurol Neurosurg Psychiatry 73: 199-201.
5. Maekawa S, Leigh NP, King A, Jones E, Steele JC, et al. (2009) TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations. Neuropathology 29: 672-683.
6. Zhong ZH, Deane R, Ali Z, Parisi M, Shapovalov Y, et al. (2008) ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11: 420-422.
7. Wilson ME, Boumaza I, Lacomis D, Bowse R, (2010) Cystatin C: A Candidate Biomarker for Amyotrophic Lateral Sclerosis. PLoS ONE 5: 15133.
8. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM, (2007) CSF Neurofilament light levels in amyotrophic lateral sclerosis: Impact of SOD1 genotype. Eur J Neurol 14: 1329-1333.
9. Zhou JY, Afjehi-Sadat L, Asress S, Duong DM, Cudkowicz M, et al. (2010) Galectin-3 Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis: Discovery by a Proteomics Approach. J Proteome Res 9: 5133-5141.
10. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, et al. (2005) Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1: 101-108.
11. Blasco H, Corcia P, Moreau C, Veau S, Fournier C, et al. (2010) H-1-NMR-Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis. Plos One 5: e13223.
12. Ihara Y, Nobukuni K, Takata H, Hayabara T, (2005) Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res 27: 105-108.
13. Paraskevas GP, Kapaki E, Libitaki G, Zournas C, Segditsa I, et al. (1997) Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol Scand 96: 88-90.
14. Wuolikainen A, Hedenström M, Moritz T, Marklund SL, Antti H, et al. (2009) Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS. Amyotrophic Lateral Sclerosis 10: 229-236.
15. Felbecker A, Camu W, Valdmanis PN, Sperfeld AD, Waibel S, et al. Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic? J Neurol Neurosurg Psychiatry 81: 572-577.
16. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, et al. (2006) Loss-of-function ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 38: 411-413.
17. Gros-Louis F, Andersen PM, Dupre N, Urushitani M, Dion P, et al. (2009) Chromograinin B variats as a risk factor and modifier of disease onset for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 106: 21777-21782.
18. Sreedharan J, Blair IP, Tripathi VB, Hu X, Chance C, et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319: 1668-1672.
19. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323: 1205-1208.
20. Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, et al. (2006) ALS phenotypes with mutations in CHMP2B (Charged Multivesicular Body Protein 2B). Neurology 67: 1074-1077.
21. Schymick JC, Yang Y; Andersen PM, Vonsattel JP, Greenway M, et al. (2007) Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J Neurol Neurosurg Psychiatry 78: 754-756.
22. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, et al. (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465: 223-226.
23. Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, et al. (2010) Ataxin-2 intermediate length polyglutamine expansions are associated with increased risk for ALS. Nature 466: 1069-1075.
24. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, et al. (2007) Proposed minimum reporting standards forchemical analysis. Metabolomics 3: 211-221.
25. Bylesjo M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, et al. (2006) OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometrics 20: 341-351.
26. Trygg J, Wold S, (2002) Orthogonal projections to latent structures (O-PLS). J Chemometrics 16: 119-218.
27. Eriksson L, Trygg J, Wold S, (2008) CV-ANOVA for significance testing of PLS and OPLS® models. J Chemometrics 22: 594-600.
28. Brouns R, Van Hemelrijck A, Drinkenburg WH, Van Dam D, De Surgeloose D, et al. (2010) Excitatory amino acids and monoaminergic neurotransmitters in cerebrospinal fluid of acute ischemic stroke patients. Neurochem Int 56: 865-870.
29. Zoccolella S, Simone IL, Lamberti P, Specchio LM, Samarelli V, et al. (2008) Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology 70: 222-225.
30. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, et al. (1990) Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28: 18-25.
31. Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, et al. (2002) Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 193: 73-78.
32. Perry TL, Krieger C, Hansen S, Eisen A, (1990) Amyotrophic-Lateral-Sclerosis- Amino-Acid Levels in Plasma and Cerebrospinal-Fluid. Ann Neurol 28: 12-17.
33. Tachikawa M, Kasai Y, Takahashi M, Fujinawa J, Kitaichi K, et al. (2008) The blood-cerebrospinal fluid barrier is a major pathway of cerebral creatinine clearance: involvement of transporter-mediated process. J Neurochem 107: 432-442.
34. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425-1431.